You are here: Industry Insights > HIV

News List

First patient treated with potentially curative HIV cell and gene therapy europeanpharmaceuticalreview
June 03, 2021
The first-in-human study will evaluate the safety and efficacy AGT103-T, a cell and gene therapy product for HIV, in up to six participants.
ViiV Healthcare starts rolling submission of cabotegravir for HIV prevention pharmaceutical-technology
May 06, 2021
ViiV Healthcare has begun a rolling submission of a new drug application (NDA) with the US Food and Drug Administration (FDA) for its long-acting cabotegravir to prevent human immunodeficiency virus (HIV) or pre-exposure prophylaxis (PrEP).
CytoDyn and Biomm enter leronlimab supply agreement pharmaceutical-technology
April 09, 2021
CytoDyn (CYDY) and Biomm have signed an exclusive supply and distribution agreement that will enable the latter to market CCR5 antagonist leronlimab (PRO 140) in Brazil on receiving regulatory approval.
Gilead, Merck sign pact to develop, commercialise long-acting HIV treatment combinations expresspharma
March 16, 2021
Gilead Sciences and Merck, known as MSD outside the US and Canada, announced that they have entered into an agreement to co-develop and co-commercialise long-acting treatments in HIV that combine Gilead’s investigational capsid inhibitor, lenacapavir ...
Maturation inhibitor shown to be safe and effective in Phase II HIV trial europeanpharmaceuticalreview
March 12, 2021
The highest doses of the novel maturation inhibitor, GSK3640254, had the greatest antiviral activity and were shown to be safe in 34 treatment-naïve adults with HIV.
Gilead’s HIV therapy Biktarvy demonstrates long-term sustained efficacy pharmatimes
March 08, 2021
Gilead Sciences has revealed new, four-year data from two Phase III studies evaluating Biktarvy for the treatment of HIV-1 in treatment-naïve adults.
Abbott researchers find rare group of people with controlled HIV who could be a key to unlocking cure worldpharmanews
March 04, 2021
Abbott announced today that a team of scientists has found an unusually high number of people in the Democratic Republic of Congo (DRC) who test positive for HIV antibodies, but have low to non-detectable viral load counts - without the use of ...
Sales of injectable anti-HIV therapeutics will reach $2 billion in 2029: GlobalData expresspharma
March 01, 2021
Cabotegravir-based therapies are projected to generate 79 per cent of the sales of injectable therapeutics in the HIV market in 2029.
Researchers at IIT Madras pave way for more effective HIV-AIDS drugs expresspharma
February 20, 2021
The research team have shown that introducing electrostatic interaction sites on potential drug molecules can enhance the efficacy of the antiviral drug against the HIV virus.
ViiV’s Rukobia receives marketing authorisation in Europe for HIV treatment pharmaceutical-technology
February 10, 2021
GlaxoSmithKline’s (GSK) ViiV Healthcare has announced the European Marketing Authorisation of its Rukobia (fostemsavir) 600mg extended-release tablets for use in combination with antiretroviral (ARV) therapies for treating adults with ...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 24 25 Next page